Trial Profile
Open-Label, Multicenter Study of D07001-Softgel Capsules (Oral Gemcitabine Hydrochloride) in Subjects With Unresectable, Metastatic or Locally Advanced Gastrointestinal (GI) Cancer in Dose-Escalation Phase and in Subjects With Advanced Biliary Tract Cancer (BTC) Following Primary Chemotherapy or Combined Chemoradiotherapy (CCRT) in Dose-Expansion Phase
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 28 Nov 2023
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary)
- Indications Cholangiocarcinoma; Gallbladder cancer; Gastrointestinal cancer
- Focus Adverse reactions
- Sponsors INNOPHARMAX
- 01 Nov 2023 Status changed from discontinued to completed.
- 06 Jun 2023 Results from two phase 1 studies NCT01800630, NCT03531320 assessing dose-limiting toxicity (DLT), pharmacokinetics (PK), bioavailability (BA) and maximum tolerated dose (MTD) of D07001-F4 and D07001-softgel capsules in subjects with refractory, advanced solid tumors presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 25 Aug 2021 Status changed from active, no longer recruiting to discontinued.